Pharmaceutical Intermediate Market Business Growth

0

Pharmaceutical Intermediates Market

The Pharmaceutical Intermediates market 2022 research report is segmented into several key regions, with production, consumption, revenue (USD Million), market share and growth rate of Pharmaceutical Intermediates in these regions, from 2022 to 2028 (forecast), covering North America, Europe, Asia-Pacific, Middle East and Africa, South and Central America.

The Pharmaceutical Intermediates Market is expected to reach USD 37,290.33 million in 2028 from USD 27,356.70 million in 2020. The market is expected to grow with a CAGR of 4.2% from 2022 to 2028.

Download a sample PDF copy at:
https://www.theinsightpartners.com/sample/TIPRE00005559/?utm_source=OpenPR&utm_medium=10376

Antibiotic intermediates are products used to produce antibiotics. For example, the intermediate 7-aminodeacetoxy-cephalosporanic acid which is used to make semi-synthetic cephalosporins. Similarly, 6-aminopenicillanic acid is an intermediate used to make semi-synthetic penicillins. Antibiotics are antimicrobial drugs that kill or prevent the growth of bacterial infections in humans and animals. These can be taken orally, topically, and intravenously (IV).
The segment is expected to grow rapidly owing to the increasing prevalence of infectious diseases and government support for antibiotics to eradicate infectious diseases. In addition, an increase in antibiotic resistance infections should require the development of new drugs.

Asia-Pacific countries are emerging as attractive outsourcing locations for the pharmaceutical and biopharmaceutical industries. Low manufacturing and operating costs in China and India are key factors driving the pharmaceutical manufacturing business in the region. The recent growth of the pharmaceutical industry in these two countries indicates a positive outlook for the pharmaceutical intermediates market. According to the India Brand Equity Foundation (IBEF), an initiative of the Ministry of Commerce and Industry, Government of India, the value of the pharmaceutical industry in India is expected to reach $100 billion by 2025. pharmaceuticals exported from India was worth US$16.3 billion in 2020; these exports include drug formulations, bulk drugs, intermediates, biologics, and herbal products.

The booming domestic pharmaceutical market in the APAC region and the growing number of drugs under development are opening up new avenues for contract manufacturers as well as generic drug manufacturing in the region. According to IBEF, India’s domestic pharmaceutical market revenue reached US$20.03 billion (INR 1.4 crore) in 2019, increasing year-on-year (year-on-year) by 9.8% from US$18.12 billion (INR 129,015 crore) in 2018. Additionally, to meet the growing demand, many contracted organizations are expanding their manufacturing capabilities, further driving the growth of the market. For example, in January 2020, STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec, opened a new large-scale oligonucleotide API manufacturing plant in China. Thus, emerging markets hold high potential and huge revenue generation opportunities for continuous pharmaceutical manufacturing companies.

The pharmaceutical intermediates market primarily includes players such as companies such as Pfizer, Inc, Dishman Group, Dextra Laboratories Limited, Sanofi Winthrop Industries SA, Vertellus Holdings LLC, BASF SE, Lianhetech, Codexis, Midas Pharma GmbH, and Chiracon GmbH. The companies have implemented various strategies which have helped in the growth of the business and in turn have led to various changes in the market.

Companies used organic strategies such as product launches, expansion, and endorsements. While the inorganic strategies such as mergers and acquisitions, partnerships, collaborations, have been widely observed in the pharmaceutical intermediates market.
Several organic approaches, such as product launches and expansion of the pharmaceutical intermediates market, have resulted in positive market growth. Likewise, inorganic strategies such as mergers and acquisitions and collaboration have helped the company to strengthen its revenue, which enables it to hold a strong position in the market.

Buy the report on:
https://www.theinsightpartners.com/buy/TIPRE00005559/?utm_source=OpenPR&utm_medium=10376

Contact us:

If you have any questions about this report or would like further information, please contact us:
Contact person: Sameer Joshi
Email: [email protected]
Phone: +1-646-491-9876

About Insight Partners:

The Insight Partners is one of the industry’s leading providers of actionable intelligence research. We help our clients find solutions to their research needs through our syndicated research and advisory services. We specialize in industries such as Semiconductors and Electronics, Aerospace and Defense, Automotive and Transportation, Manufacturing and Construction, Technology, Chemicals and Materials.
We offer our customers several ways to customize search to suit their specific needs and budget.

This press release was published on openPR.

Share.

Comments are closed.